These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7726506)

  • 1. Subinhibitory concentrations of cefpodoxime alter membrane protein expression of Actinobacillus actinomycetemcomitans and enhance its susceptibility to killing by neutrophils.
    Baker PJ; Busby WF; Wilson ME
    Antimicrob Agents Chemother; 1995 Feb; 39(2):406-12. PubMed ID: 7726506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killing of Actinobacillus actinomycetemcomitans and Haemophilus aphrophilus by human polymorphonuclear leukocytes in serum and saliva.
    Holm A; Kalfas S; Holm SE
    Oral Microbiol Immunol; 1993 Jun; 8(3):134-40. PubMed ID: 8233566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azithromycin enhances phagocytic killing of Aggregatibacter actinomycetemcomitans Y4 by human neutrophils.
    Lai PC; Schibler MR; Walters JD
    J Periodontol; 2015 Jan; 86(1):155-61. PubMed ID: 25186779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ciprofloxacin on killing of Actinobacillus actinomycetemcomitans by polymorphonuclear leukocytes.
    Cacchillo DA; Walters JD
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1980-4. PubMed ID: 12019120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clindamycin on neutrophil killing of gram-negative periodontal bacteria.
    Baker PJ; Wilson ME
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1521-7. PubMed ID: 3056238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opsonic antibody activity against Actinobacillus actinomycetemcomitans in patients with rapidly progressive periodontitis.
    Sjöström K; Darveau R; Page R; Whitney C; Engel D
    Infect Immun; 1992 Nov; 60(11):4819-25. PubMed ID: 1398993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Killing of Actinobacillus actinomycetemcomitans by the human neutrophil myeloperoxidase-hydrogen peroxide-chloride system.
    Miyasaki KT; Wilson ME; Genco RJ
    Infect Immun; 1986 Jul; 53(1):161-5. PubMed ID: 3013779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced susceptibility of Staphylococcus aureus pretreated with cefepime and cefpodoxime to leukocyte activity.
    Herrera I; Martinez P; Perez P; Garcia Y; Gomez-Lus ML; Prieto J
    J Chemother; 1995 Nov; 7 Suppl 4():23-5. PubMed ID: 8904094
    [No Abstract]   [Full Text] [Related]  

  • 9. Bactericidal activities of synthetic human leukocyte cathepsin G-derived antibiotic peptides and congeners against Actinobacillus actinomycetemcomitans and Capnocytophaga sputigena.
    Miyasaki KT; Bodeau AL; Pohl J; Shafer WM
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2710-5. PubMed ID: 8109940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative and nonoxidative killing of Actinobacillus actinomycetemcomitans by human neutrophils.
    Miyasaki KT; Wilson ME; Brunetti AJ; Genco RJ
    Infect Immun; 1986 Jul; 53(1):154-60. PubMed ID: 3013778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin G2 antibodies promote neutrophil killing of Actinobacillus actinomycetemcomitans.
    Wilson ME; Bronson PM; Hamilton RG
    Infect Immun; 1995 Mar; 63(3):1070-5. PubMed ID: 7868229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaerobic neutrophil-dependent killing of Actinobacillus actinomycetemcomitans in relation to the bacterial leukotoxicity.
    Johansson A; Sandström G; Claesson R; Hänström L; Kalfas S
    Eur J Oral Sci; 2000 Apr; 108(2):136-46. PubMed ID: 10768727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of antibody, complement and neutrophils in host defense against Actinobacillus actinomycetemcomitans.
    Wilson ME; Genco RJ
    Immunol Invest; 1989; 18(1-4):187-209. PubMed ID: 2659510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of high-avidity binding of human neutrophil myeloperoxidase in the killing of Actinobacillus actinomycetemcomitans.
    Miyasaki KT; Zambon JJ; Jones CA; Wilson ME
    Infect Immun; 1987 May; 55(5):1029-36. PubMed ID: 3032796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro evaluation of cefpodoxime.
    Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylcholine is located in Aggregatibacter actinomycetemcomitans fimbrial protein Flp 1.
    Ihalin R; Zhong D; Karched M; Chen C; Asikainen S
    Med Microbiol Immunol; 2018 Nov; 207(5-6):329-338. PubMed ID: 30056510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential killing of Actinobacillus actinomycetemcomitans and Capnocytophaga spp. by human neutrophil granule components.
    Miyasaki KT; Bodeau AL; Flemmig TF
    Infect Immun; 1991 Oct; 59(10):3760-7. PubMed ID: 1894375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of the bactericidal effect of cefpodoxime using an in vitro pharmacokinetic model].
    Caisson A; Chantot JF
    Pathol Biol (Paris); 1991 Oct; 39(8):774-9. PubMed ID: 1762835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antimicrobial susceptibility of periodontopathic Actinobacillus actinomycetemcomitans to roxithromycin and erythromycin.
    Piccolomini R; Di Bonaventura G; Catamo G; Picciani C; Paolantonio M
    Oral Microbiol Immunol; 1997 Dec; 12(6):366-71. PubMed ID: 9573812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.